Elizabeth Kaufman, MD
Emergency Medicine · San Diego, CANPI 1942644679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Johnson & Johnson at 55.0% of the total. Reporting peaked in 2019 at $175 and has fallen 72.5% since, to $48 in 2024.
Across 7 payments — averaging $49.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$192
- Teva Pharmaceuticals USA, Inc.$127
- Merck$15
- AstraZeneca$14
Across 8 payments — averaging $19,185 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$153K
What the payments were for
- Food & beverage$348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 3 | $192 |
| Teva Pharmaceuticals USA, Inc. | 2 | $127 |
| Merck | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$348 in reported general payments places this provider in the 85th percentile of 6,006 emergency medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CefuroximeCefuroxime Axetil | 25 | $322 |
| Azithromycin | 16 | $70 |
| Methylprednisolone | 11 | $34 |
| Meloxicam | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in San Diego
- Paul PearigenSan Diego$208K
- Christopher CoyneSan Diego$93K
- Bradley BaileySan Diego$35K
- Andrew DesjardinsSan Diego$35K
- Michael NielsenSan Diego$19K
- Michael BlueLone Pine$915K
- Andrew AccardiEncinitas$383K
- Fredrick Melik-AbrahamianSylmar$354K
- Graham WalkerStanford$309K
- Douglas WhiteOakland$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.